Novavax to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021

Rhea-AI Summary

Novavax, a biotechnology company focused on next-generation vaccines, announced its participation in Citi's 16th Annual BioPharma Virtual Conference on September 9, 2021. The event will feature a fireside chat discussing Novavax' COVID-19 vaccine candidate, NVX-CoV2373. Key participants from Novavax, including Dr. Gregory M. Glenn and John J. Trizzino, will represent the company. A replay of the session will be available on Novavax's website for 90 days following the event.

The company continues its late-stage trials for NVX-CoV2373 and its influenza vaccine, NanoFlu.

GAITHERSBURG, Md., Sept. 7, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in Citi's 16^th Annual BioPharma Virtual Conference 2021 investor conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Conference Details: Fireside Chat
Date:	Thursday, September 9, 2021
Time:	4:10 – 4:55 p.m. Eastern Time (ET)
Moderator:	Michael Guba
Novavax participants:	Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer
Conference
Event:	Investor meetings
Date:	Thursday, September 9, 2021

A replay of the recorded fireside session will be available through the events page of the Company's website at ir.novavax.com for 90 days.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:     
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Alexandra Roy | 617-221-9197
aroy@soleburytrout.com

Media
Alison Chartan | 240-720-7804
Laura Keenan | 202-709-7521
media@novavax.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-citis-16th-annual-biopharma-virtual-conference-2021-301370261.html

SOURCE Novavax, Inc.

FAQ

When will Novavax present at Citi's BioPharma Conference 2021?

Novavax will present at Citi's 16th Annual BioPharma Virtual Conference on September 9, 2021.

What is the time of Novavax's presentation at the conference?

The presentation will take place from 4:10 – 4:55 p.m. Eastern Time (ET) on September 9, 2021.

Who are the participants from Novavax at the conference?

Participants from Novavax include Dr. Gregory M. Glenn and John J. Trizzino.

What will Novavax discuss during the conference?

Novavax will discuss its COVID-19 vaccine candidate, NVX-CoV2373.

Where can I watch the Novavax conference replay?

The replay will be available on Novavax's website for 90 days after the event.